TTX-030 + gemcitabine + nab-paclitaxel

TTX-030 + gemcitabine + nab-paclitaxel is an investigational combination therapy for the first-line treatment of metastatic pancreatic adenocarcinoma. - **TTX-030** is a first-in-class, anti-CD39 monoclonal antibody designed to inhibit the activity of CD39, an ectonucleotidase that converts ATP to AMP, the initial step in adenosine generation in the tumor microenvironment. By preventing the formation of immunosuppressive adenosine and maintaining immune-activating ATP, TTX-030 aims to bolster both innate and adaptive anti-tumor immunity. - **Gemcitabine** is a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis and induces apoptosis. - **Nab-paclitaxel** (albumin-bound paclitaxel) is a taxane chemotherapy that inhibits microtubule disassembly, leading to cell cycle arrest and apoptosis. This regimen is under clinical evaluation as a first-line treatment for metastatic pancreatic cancer. Phase 1/2 studies show promising efficacy, especially in biomarker-enriched populations (e.g., HLA-DQ high patients)[1][2][3][4][5][7][8].

Brand names

Abraxane (nab-paclitaxel)Gemzar (gemcitabine)

Other names

albumin-bound paclitaxel (for nab-paclitaxel)